Corient Capital Partners, LLC Viking Therapeutics, Inc. Transaction History
Corient Capital Partners, LLC
- $1.34 Billion
- Q3 2022
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
469Shares Held
63.2MCall Options Held
5.76MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$346 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$205 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$159 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$72.1 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$63.8 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.61B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...